Both the white blood cell count and the proportion of peripheral blood immature cells at diagnosis were greater in the CDKN2A/B deletion group than in the non-deletion group, suggesting that pediatric patients with CDKN2A/B deletion had a greater tumor burden at diagnosis. Here, CDKN2A is linked to neoplasm.